## Amendments to the Claims

Please amend the claims as follows:

1. (original) A tetrahydroquinoline derivative according to Formula 1,

Formula I

or a pharmaceutically acceptable salt thereof, wherein

R<sup>1</sup> and R<sup>2</sup> are H or Me

R<sup>3</sup> is H, hydroxy, (1-4C)alkoxy, (di)(1-4C)alkylamino(2-4C)alkoxy or (2-

6)heterocycloalkyl(2-4C)alkoxy

R<sup>4</sup> is H, OH, (1-4C)alkoxy or R<sup>7</sup>

R<sup>5</sup> is H, OH, (1-4C)alkoxy or R<sup>7</sup>

with the proviso that if R<sup>4</sup> is H, R<sup>5</sup> is not H, OH or (1-4C)alkoxy and that if R<sup>5</sup> is H,

R<sup>4</sup> is not H, OH or (1-4C)alkoxy

R<sup>6</sup> is (2-5C)heteroaryl, (6C)aryl, (3-8C)cycloalkyl, (2-6C)heterocycloalkyl or (1-

6C)alkyl

R<sup>7</sup> is amino, (di)(1-4C)alkylamino, (6C)arylcarbonylamino, (6C)arylcarbonyloxy,

(2-5C)heteroarylcarbonylamino, (2-5C)heteroarylcarbonyloxy, R<sup>8</sup>-(2-

4C)alkylamino, R<sup>8</sup>-(2-4C)alkoxy, R<sup>9</sup>-methylamino or R<sup>9</sup>-methoxy

R<sup>8</sup> is hydroxy, amino, (1-4C)alkoxy, (di)(1-4C)alkylamino, (2-6C)heterocycloalkyl,

(2-6C)heterocycloalkylcarbonylamino, (di)(1-4C)alkylaminocarbonylamino, (1-

- 4C)alkoxycarbonylamino and R<sup>9</sup> is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (2-5C)heteroaryl or (6C)aryl.
- 2. (original) The tetrahydroquinoline derivative of claim 1 wherein R<sup>6</sup> is (2-5C)heteroaryl, (6C)aryl, (3-8C)cycloalkyl or (1-6C)alkyl.
- 3. (currently amended) The tetrahydroquinoline derivative of claim 1 claims 1 or 2 wherein R<sup>7</sup> is (di)(1-4C)alkylamino, (2-5C)heteroarylcarbonyloxy, R<sup>8</sup>-(2-4C)alkoxy, R<sup>9</sup>-methylamino or R<sup>9</sup>-methoxy.
- 4. (currently amended) The tetrahydroquinoline derivative of <u>claim 3 elaims 1-3</u> wherein R<sup>8</sup> is amino, (di)(1-4C)alkylamino, (2-6C)heterocycloalkyl or (2-6C)heterocycloalkylcarbonylamino.
- 5. (currently amended) The tetrahydroquinoline derivative of claim 2 claims 1-4 wherein R<sup>7</sup> is (di)(1-4C)alkylamino, R<sup>8</sup>-(2-4C)alkoxy, R<sup>9</sup>-methylamino or R<sup>9</sup>-methoxy.
- 6. (currently amended) The tetrahydroquinoline derivative of claim 5 claims 1-5 wherein R<sup>8</sup> is amino, (di)(1-4C)alkylamino or (2-6C)heterocycloalkyl.
- 7. (currently amended) The tetrahydroquinoline derivative of <u>claim 6</u> claims 1-6 wherein R<sup>8</sup> is (di)(1-4C)alkylamino or (2-6C)heterocycloalkyl.
- 8. (currently amended) The tetrahydroquinoline derivative of claim 1 elaims 1-7 wherein R<sup>7</sup> is (di)(1-4C)alkylamino, R<sup>8</sup>-(2-4C)alkoxy, R<sup>9</sup>-methylamino or R<sup>9</sup>-methoxy.
- 9. (currently amended) The tetrahydroquinoline derivative of claim 8 elaims 1-8 wherein R<sup>6</sup> is (2-5C)heteroaryl or (6C)aryl.

- 10. (currently amended) The tetrahydroquinoline derivative of <u>claim 1</u> <u>claims 1-9</u> wherein R<sup>6</sup> is (4-5C)heteroaryl or (6C)aryl and R9 is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (3-5C)heteroaryl or (6C)aryl.
- 11. (currently amended) The tetrahydroquinoline derivative of <u>claim 1</u> <u>claims 1-10</u> wherein R<sup>7</sup> is (di)(1-4C)alkylamino, R<sup>8</sup>-ethoxy, R<sup>9</sup>-methylamino or R<sup>9</sup>-methoxy and R<sup>9</sup> is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (3-5C)heteroaryl or (6C)aryl.
- 12. (currently amended) The tetrahydroquinoline derivative of <u>claim 1</u> <u>claims 1-11</u> wherein R<sup>8</sup> is[[,]] (di)(1-4C)alkylamino[[,]] <u>or</u> (4-5C)heterocycloalkyl and R<sup>9</sup> is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (3-5C)heteroaryl or (6C)aryl.
- 13. (currently amended) A pharmaceutical composition comprising the tetrahydroquinoline derivative of <u>claim 1</u> any one of claims 1-12 and <u>at least one</u> pharmaceutically suitable <u>auxiliary auxiliaries</u>.
- 14. (cancelled)
- 15. (cancelled)
- 16. (new) A method of fertility regulation comprising administering an FSH receptor activity modulating amount of the pharmaceutical composition of claim 13.